Weil has advised Gyrus Capital, a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors (“Gyrus”), on the closing of a €600m single-asset continuation vehicle for Essential Pharma, an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas. The continuation vehicle was led by AlpInvest.

Simultaneously Weil advised Gyrus on the closing of a GP-led secondary transaction whereby StepStone Group provided a liquidity solution to existing investors in Gyrus 1 LP, a Gyrus managed vehicle invested in dss+, a leading provider of specialist operations management consulting services with a purpose of saving lives and creating a sustainable future.

The Weil team was led by Private Funds partners James Sargent, Peter Boulle and Sophie Smith and Tax partners Aron Joy and Andrew Morris; with support from Private Funds counsel Nick Roxburgh; Tax counsel Daniella Abel; Private Funds associates Carl Suard, Luke Costello, Abdul Wahaab Din and Bernard Mustafa; and Tax associates Jack O’Donohue and Courtney Baltz.